Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Moodys
McKesson
Mallinckrodt
McKinsey

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

DAURISMO Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Daurismo, and what generic alternatives are available?

Daurismo is a drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-eight patent family members in forty-five countries.

The generic ingredient in DAURISMO is glasdegib maleate. One supplier is listed for this compound. Additional details are available on the glasdegib maleate profile page.

US ANDA Litigation and Generic Entry Outlook for Daurismo

  Start Trial

Daurismo will be eligible for patent challenges on November 21st, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 13th, 2036. This may change due to patent challenges or generic licensing.

Summary for DAURISMO
International Patents:68
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 39
Patent Applications: 5
Drug Prices: Drug price information for DAURISMO
DailyMed Link:DAURISMO at DailyMed
Drug patent expirations by year for DAURISMO
Drug Prices for DAURISMO

See drug prices for DAURISMO

Generic Entry Opportunity Date for DAURISMO
Generic Entry Date for DAURISMO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for DAURISMO
Synonyms for DAURISMO
1-((2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate salt
1-((2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)ureamaleatesalt
1-((2R,4R)-2-(1H-benzo[d]iMidazol-2-yl)-1-Methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea(PF-04449913)
1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea
1095173-27-5
2030410-25-2
2640AH
4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)-benzonitrile
BC600416
BDBM50385635
C21H22N6O
CHEBI:145428
CHEMBL2043437
CS-2731
D10636
D11107
Daurismo (TN)
DB11978
EX-A858
Glasdegib
Glasdegib (PF-04449913)
Glasdegib (USAN/INN)
Glasdegib [USAN:INN]
Glasdegib maleate
Glasdegib maleate (JAN)
glasdegib-pf-04449913
Glasdegib(PF-04449913)
glasdegibum
GTPL8201
HY-16391
J-690029
K673DMO5H9
LQT-B00722
MFCD25976839
N-[(2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)urea
N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-N'-(4-cyanophenyl)urea
NCGC00378600-02
PF 04449913
PF-04449913
PF-04449913 maleate
PF-04449913 maleate salt, >=98% (HPLC)
PF-04449913;Glasdegib
PF-4449913
PF-913
Q27077810
QC-11459
SB16679
SCHEMBL18171548
SCHEMBL2068480
SFNSLLSYNZWZQG-VQIMIIECSA-N
TH2EV99S4Z
UNII-K673DMO5H9
UNII-TH2EV99S4Z
Urea, N-((2R,4R)-2-(1H-benzimidazol-2-yl)-1-methyl-4-piperidinyl)-N'-(4-cyanophenyl)-, (2Z)-2-butenedioate (1:1)
Urea, N-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methyl-4-piperidinyl]-N'-(4-cyanophenyl)-
Z-3230
ZINC68251434

US Patents and Regulatory Information for DAURISMO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-002 Nov 21, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-002 Nov 21, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Pfizer Inc DAURISMO glasdegib maleate TABLET;ORAL 210656-001 Nov 21, 2018 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Colorcon
Express Scripts
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.